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The JAK2 tyrosine kinase is a critical mediator of
cytokine-induced signaling. It plays a role in the
nucleus, where it regulates transcription by phos-
phorylating histone H3 at tyrosine 41 (H3Y41ph).
We used chromatin immunoprecipitation coupled
to massively parallel DNA sequencing (ChIP-seq) to
define the genome-wide pattern of H3Y41ph in
human erythroid leukemia cells. Our results indicate
that H3Y41ph is located at three distinct sites: (1)
at a subset of active promoters, where it overlaps
with H3K4me3, (2) at distal cis-regulatory elements,
where it coincides with the binding of STAT5, and
(3) throughout the transcribed regions of active,
tissue-specific hematopoietic genes. Together,
these data extend our understanding of this con-
served and essential signaling pathway and provide
insight into the mechanisms by which extracellular
stimuli may lead to the coordinated regulation of
transcription.INTRODUCTION
The canonical JAK2-STAT5 pathway is one of the most widely
studied cellular signaling cascades and is critical for normal
hematopoiesis (Decker and Mu¨ller, 2012). It is also now estab-
lished that hyperactivation of JAK-STAT signaling is a common
event in several hematological neoplasms (Chen et al., 2012).
These findings underline the importance of a comprehensive
understanding of the function of this signaling pathway.
Until recently, JAKs were largely ascribed the cytoplasmic
function of phosphorylating STAT family members to promote
STAT dimerization, nuclear translocation, and binding to cis-
regulatory elements to regulate transcription (Decker andMu¨ller,
2012). However, recent reports have highlighted that members
of the JAK family also appear to have specific roles in the nuclei
of various tissues (Dawson et al., 2009; Griffiths et al., 2011;470 Cell Reports 2, 470–477, September 27, 2012 ª2012 The AuthorKamakura et al., 2004; Lefrancois-Martinez et al., 2011; Liu
et al., 2011; Nilsson et al., 2006; Rui et al., 2010). Indeed, we
have demonstrated that JAK2 functions as a histone tyrosine
kinase, phosphorylating H3Y41 to regulate chromatin binding
of HP1a in hematopoietic cells (Dawson et al., 2009). H3Y41ph
represents the only characterized tyrosine phosphorylation in
nonvariant mammalian histones. Here we report the genome-
wide analysis of this modification by chromatin immunoprecipi-
tation (ChIP) coupled to massively parallel DNA sequencing
(ChIP-seq). These data provide insights into the mechanisms
of transcription control exerted by this conserved and essential
signaling pathway.
RESULTS
H3Y41ph Is Associated with Active Promoters
H3Y41ph is present at the transcriptional start site (TSS) of the
LMO2 gene, overlapping the active H3K4me3 modification
(Dawson et al., 2009), and is linked to transcriptional activation.
To ascertainwhether this relationship ismaintained on a genomic
scale, we generated a global map of the spatial distribution
of H3Y41ph and H3K4me3 by performing ChIP-seq using
chromatin from human erythroid leukemia (HEL) cells. When
ranked in ascending order of H3Y41ph and H3K4me3 levels,
global analysis of gene promoters demonstrates that these
two histone modifications are coincident at many loci (Figure 1A,
areas I and II).
A detailed analysis then examined the global relationship
between H3K4me3 and H3Y41ph across TSSs. 28,996 TSSs
were split into 10 sets (the first nine segments have 2,900 and
the tenth has 2,896) based on levels of H3K4me3 (Figure 1B).
These sets were ranked according to the levels of H3K4me3 at
the TSS, as this has previously been shown to quantitatively
reflect transcriptional activity; the most highly transcribed
genes have the highest levels of H3K4me3 and vice versa (Barski
et al., 2007; Min et al., 2011). Once ranked according to
H3K4me3 levels, we then looked at the distribution and levels
of H3Y41ph across the same promoter cohorts. This analysis
revealed that, when present, H3Y41ph is often at the TSS
of active genes, where it correlates closely with H3K4me3s
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Figure 1. H3Y41ph Is Associated with Active Transcription
(A) Sequence tags for H3K4me3 andH3Y41phwere determined at all TSSs. Density profiles using quantile-normalized ranks of each region for their relative levels
of H3K4me3 (x axis) and H3Y41ph (y axis) were divided into six subdivisions: (I) correlated H3K4me3 and H3Y41ph, (II) low-H3K4me3 and low-H3Y41ph, (III) low-
H3K4me3 andmid/high-H3Y41ph, (IV) mid/high-H3K4me3 and low-H3Y41ph, (V) high-H3K4me3 andmid-H3Y41ph, and (VI) high-H3K4me3 and mid-H3Y41ph.
(B) Mean enrichment pattern for H3K4me3 was profiled across all annotated TSSs. Populations used were ranked according to levels of H3K4me3 enrichment
and then split into 10 equal sets.
(C) The mean enrichment pattern for H3Y41ph was profiled across the same populations of TSSs as those described in (B).
See also Figure S1 and Table S1.(Figure 1C). Importantly, selective inhibition of JAK2 activity
for 4 hours demonstrated a significant global reduction of
H3Y41ph at the TSS of genes marked with this histonemodifica-
tion (Figure S1). Overall, these data indicate that, as predicted
from our previous analysis of the LMO2 gene, H3Y41ph coin-
cides with H3K4me3 surrounding the TSSs of a subset of tran-
scriptionally active genes.
H3Y41ph Marks Intragenic Elements with STAT
Binding Sites
Analysis of individual gene loci revealed that H3Y41ph is also en-
riched at noncoding regions of several JAK-STAT target genes,
such as CISH and PIM1 (Figures 2A and 2E). These sites have
a high degree of sequence conservation and are also marked
by H3K4me1, consistent with a potential function as distal
cis-regulatory elements (Figure S2A). Indeed, some of these
elements have already been defined as enhancer elements,
such as those present at ID1 (Wood et al., 2009) and CISH
(Nagy et al., 2009). Together these data raise the possibility
that H3Y41ph also delineates a subset of conserved elements
outside of genes, at least some of which are known functional
STAT5 enhancers.
It is firmly established that JAK2 and STAT5 physically and
functionally interact (Barahmand-Pour et al., 1998). Thus far,
only a few direct target genes bound by STAT5, such as CISH,
PIM1, ID1, and BCLXL, have been characterized in the erythroid
lineage (Dumon et al., 1999; Matsumoto et al., 1997; Mui et al.,
1996; Wood et al., 2009). As HEL cells are a model cell line for
malignant erythropoiesis, we investigated the genome-wide
distribution of STAT5 by ChIP-seq to see if it coincides with
H3Y41ph. Bioinformatic analysis of our newly generated
STAT5 ChIP-seq data set identified 676 high-confidence
STAT5 binding sites (Table S1). Importantly, the few previously
known functional STAT5 binding sites, such as those present
at ID1 and BCLXL, were all identified as significant peaks (Fig-
ure S2B). Moreover, we now provide several hundred potentialCeltargets of STAT5 (Table S1), functional validation of which may
uncover new insights into mechanisms of pathogenesis in
JAK2-STAT5-driven neoplasms.
The quality of our STAT5 ChIP-seq data set was confirmed
by an unbiased de novo motif discovery, which identified the
previously reported TTCYNRGAA STAT consensus binding
site as the only significantly enriched motif (Figure 2B). Further-
more, we observed an enrichment of STAT5 binding proximal
to gene promoters, although the vast majority of STAT5
binding events were seen in nonpromoter regions (Figure 2C).
These findings are analogous to those reported from recent
genome-wide surveys of STAT5 binding in mouse liver (Zhang
et al., 2012). Our ChIP-seq data indicate that both the
H3Y41ph modification and STAT5 binding often occur at the
same genomic regions (Figure 2E; Table S1). Indeed, when
the spatial distribution of the H3Y41ph peaks are determined
relative to the STAT5 peaks, we find that the location of
H3Y41ph is directly coincident with the STAT5 binding event
(Figures 2E and S2A).
H3Y41ph and STAT5 Binding Are Coincident
and Concomitantly Regulated by JAK2
Although we observe a significant coincidence of H3Y41ph
with STAT5, our data clearly demonstrate that the majority of
H3Y41ph is independent of STAT5 (Tables S1 and S2). Never-
theless, the coincidence of H3Y41ph with STAT5 suggests that
the interaction of JAK2/STAT5 may extend beyond the cyto-
plasm and culminate at the chromatin of a key subset of genes.
We therefore asked if JAK2 signaling coordinates both the
posttranslational modification of histones and the concomitant
binding of STAT5 to its target DNA. For this, we performed
both an H3Y41ph and STAT5 ChIP-seq analysis with chromatin
from HEL cells that had been treated with the selective JAK2
inhibitor, TG101209, for 4 hours. Global analysis demonstrated
that H3Y41ph and STAT5 binding events were significantly
decreased after JAK2 inhibition (Figures 2D and 2E). Thesel Reports 2, 470–477, September 27, 2012 ª2012 The Authors 471
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Figure 2. Genome-wide Analysis of STAT5 Binding and H3Y41ph
(A) ChIP-seq density profiles for H3K4me3 and H3Y41ph for theCISH gene showH3Y41ph enriched at the TSS and over a regulatory region (boxed) downstream
of the gene.
(B) De novo motif discovery of high confidence STAT5 peaks. When displayed as a sequence logo, it is identical to the known STAT5 consensus motif.
(C) Pie chart illustrating the distribution of STAT5 with respect to genes. The number of STAT5 peaks within 1 kb of TSSs was determined. Remaining STAT5
peaks were divided into genic and intergenic. The percentage of STAT5 at each region is shown (large pie chart). For comparison, the percentage of the genome
assignable to each region is also shown (small pie chart).
(D) Density of ChIP-seq reads across H3Y41ph and STAT5 peak regions before and after JAK2 inhibition shown as heat maps centered on peak summits with
5 kb of flanking sequence either side. Darker color indicates higher density of reads. H3Y41ph peak regions were rank ordered based on signal intensity at the
peak center divided by the average signal across the +/ 5 kb flanking region and were arranged based on relative local enrichment. The same order was used to
display the heat maps of H3Y41ph + TG101209. The same procedure was used to generate the analogous heat maps for the STAT5 peaks.
(E) The ChIP-seq density profiles for STAT5 and H3Y41ph, before and after inhibition of JAK2, shows both STAT5 and H3Y41ph enrichment is markedly reduced
at an enhancer of PIM1.
(F) Cytokine stimulation with IL3 leads to increased STAT5 binding (left panel) and H3Y41ph (right panel) at cis-regulatory elements for both PIM1 and CISH.
(G) STAT5 and JAK2 are required for H3Y41 phosphorylation. 293T cells harboring an integrated GAL4 reporter were transfected with the plasmids encoding
proteins, as illustrated. H3Y41ph levels at the promoter of the integrated reporter were monitored by ChIP-PCR. Data were normalized for H3 occupancy and are
represented relative to H3Y41ph levels in lane 1. Experiments were performed in biological triplicate. Each amplicon was analyzed in duplicate each time and
error bars represent the standard deviation for each amplicon.
See also Figure S2 and Table S1.findings are consistent with our previous results derived from
western blot analyses, where we see a global reduction in
H3Y41ph following exposure of HEL cells to a 4 hr treatment
with TG101209 (Dawson et al., 2009). The dual regulation of
H3Y41ph and STAT5 binding by JAK2 signaling is specifically
demonstrated at the PIM1 locus in Figure 2E. Several loci
identified in the ChIP-seq data were independently validated
by ChIP-PCR at various JAK2-STAT5 target genes in HEL472 Cell Reports 2, 470–477, September 27, 2012 ª2012 The Authorcells (Figure S2C). Moreover, these results were validated
using AT9283 (Dawson et al., 2010), a second chemically
distinct JAK2 inhibitor (Figure S2D). Finally, we demonstrate
the broader application of these data by observing similar
findings in SET-2 cells, a megakaryoblastic cell line contain-
ing JAK2V617F (Figure S2E). Taken together, these data are
consistent with JAK2 being a major histone kinase responsible
for H3Y41ph and indicate that signaling via JAK2 concomitantlys
regulates both H3Y41ph and STAT5 binding at certain JAK2/
STAT5 target genes.
We next asked whether cytokine induction via JAK2 dynami-
cally regulates the appearance of H3Y41ph and the binding of
STAT5 on cytokine-regulated genes. TF1 cells (cytokine-depen-
dent human erythroid-leukemia cells diploid for wild-type [WT]
JAK2) were stimulated for 1 hr with IL3, a cytokine that signals
primarily via JAK2 (Decker and Mu¨ller, 2012). The expression
of two well-characterized cytokine inducible JAK2-STAT5 target
genes, PIM1 (Mui et al., 1996) and CISH (Matsumoto et al.,
1997), were markedly increased by IL3, whereas the transcrip-
tion of the b2M housekeeping gene was unchanged (data not
shown). Importantly, ChIP analyses from the same cell popu-
lations clearly demonstrated that the increased gene expression
of PIM1 and CISH was linked to an increase of both H3Y41ph
and STAT5 at the respective PIM1 and CISH cis-regulatory
elements (Figure 2F). Notably, levels of H3Y41 and STAT5
were unaltered at the promoter of the b2M housekeeping
gene (Figure 2F). These data provide further evidence for a
communication between JAK2 and STAT5, which extends to
the chromatin interface in order to regulate transcription of
these genes.
To address the possibility that STAT5 plays a direct role in
recruiting JAK2 to phosphorylate H3Y41 at a subset of genomic
loci, we initially performed small interfering RNA (siRNA)-
mediated knockdown of STAT5 in HEL cells and monitored
both transcriptional activity and H3Y41ph/STAT5 binding at
known JAK2/STAT5 target genes. However, despite a 90%
knockdown of STAT5, transcription and H3Y41ph levels were
only modestly decreased at some (e.g., CISH) but not all
(e.g., PIM1) JAK2/STAT5 target genes (Figures S1F–S1H).
However, since trace amounts of STAT5 were sufficient for
essentially normal development and function of the original
STAT5 knockout mice (Teglund et al., 1998), the absence of
a strong knock down phenotype observed here most likely
reflects the fact that the residual 10% of STAT5 is sufficient
for near-full activity. An alternative nonmutually exclusive expla-
nation is that other STAT family members may compensate for
the reduced levels of STAT5, as previously reported (Lim and
Cao, 2006).
Due to the limitations of the siRNA approach, we chose to
investigate the role of STAT5 and JAK2 in mediating H3Y41ph
using an alternative strategy. Our method employed a chro-
mosomally integrated Gal4 reporter assay in 293T cells. This
approach allowed us to specifically address the issue of whether
STAT5 and JAK2 are both required for H3Y41ph at a synthetically
engineered chromatinized locus (Figure 2G). In this assay,
STAT5 is exogenously expressed in-frame with a Gal4 DNA
binding domain (DBD). By using ChIP assays to monitor
H3Y41ph levels at the chromatinized Gal4 reporter, we clearly
demonstrate that both STAT5 (targeted to chromatin via the
Gal4 DBD) and JAK2 are necessary to phosphorylate H3Y41 at
this site (Figures 2G, S1I, and S1J). Importantly, GAL4-STAT5
by itself does not lead to an increase in H3Y41ph, as 293T cells
contain little, if any JAK2 (Figure 2G). In this assay, we tested
human WT STAT5A and STAT5B as well as constitutively active
murine STAT5A and STAT5B and observed similar results
(Figures 2G, S1G, and S1H). These mechanistic studies areCelconsistent with our genome-wide correlation and together
suggest that STAT5 may recruit JAK2 to certain genomic loci
to phosphorylate H3Y41.
H3Y41ph Blankets Key Tissue-Specific Genes
Interrogation of the genomic distribution of H3Y41ph revealed
a third pattern unique to this histone modification, i.e., ‘‘blanket-
ing’’ of H3Y41ph over the entire coding region of a gene (Figures
3A–3C and S3A). Notably, H3Y41ph invariably also spans the
TSS at these genes (Figure 3B). In order to identify genes most
prominently blanketed by H3Y41ph, we analyzed the read
density and distribution of H3Y41ph over the entire coding
region of all annotated genes. This shows that H3Y41ph heavily
blankets only a small fraction of genes (Figures 3A and S3A),
many of which are key hematopoietic genes. Indeed, 71% of
the identified blanketed genes are enriched in hematopoietic
gene sets, and this group includes several genes, such as
GATA2, EGFL7, and TAL1 (Figure 3B), that have previously
been implicated in both normal hematopoiesis and the patho-
genesis of acute myeloid leukemia (Table S1). To control for
copy number alterations, which could lead to overrepresentation
in sequencing data, giving a spurious impression that regions of
the genome were ‘‘blanketed,’’ we performed an immunoglob-
ulin G (IgG) control from the same chromatin preparation as
the H3Y41ph results.When the IgGChIP-seq data are compared
with published genome-wide SNP6 array data in HEL cells, we
clearly observe that the ‘‘background’’ of sequencing signal
varies, as expected with the copy number (Figure S3B). In con-
trast, when we look at a locus that is blanketed by H3Y41ph,
the IgG trace over the blanketed region does not mirror the
pattern of H3Y41ph (Figure S3B). Similar results were also
observed for the STAT5 ChIP-seq data (data not shown).
Furthermore, a similar ‘‘blanketing’’ analysis for another active
histone modification, H3K4me3, does not recapitulate these
findings (Table S1).
Interestingly, the H3Y41ph-blanketed genes are not the most
highly expressed genes in HEL cells (Figure S3C). Thus, the
relatively high level of H3Y41ph spread throughout these genes
does not seem to be a consequence of a high rate of transcrip-
tion. Finally, the vast majority of heavily H3Y41ph-blanketed
genes that are responsive to JAK2 inhibition do not contain
STAT5 binding events (Table S2). These data serve to demon-
strate that, while STAT5 and potentially other STATs may target
JAK2 to certain genomic loci, this phenomenon is not ubiquitous,
and the majority of genes appear to be marked by H3Y41ph in
a STAT-independent manner. Nevertheless, it is clear that
JAK2 inhibition is sufficient to substantially reduce H3Y41ph
and gene expression, even at these STAT-independent loci
(Figure 3C; Table S2).
Together these data underline the fact that blanketing is
neither a simple attribute of transcriptional activity nor a common
feature of other active histone modifications. This raises the
possibility that H3Y41ph may ‘‘blanket’’ genes whose expres-
sion is necessary to propagate or maintain a particular cellular
state. Consistent with this notion is the fact that unbiased
interrogation of the H3Y41ph-blanketed genes in HEL cells
for common knock-out mouse phenotypes using the Genomic
Regions Enrichment of Annotations Tool (GREAT) (McLeanl Reports 2, 470–477, September 27, 2012 ª2012 The Authors 473
Figure 3. H3Y41ph Blankets Tissue-Specific Genes
(A) Heat maps showing the coverage of H3Y41ph throughout gene bodies. For each gene, the transcribed region was divided into 10 equally sized sections, and
the proportion of bases associated with H3Y41ph in each case was determined. Genes were ranked according to the median of these 10 values. Left panel,
H3Y41ph distribution throughout all 18,407 genes; middle panel, H3Y41ph distribution throughout the ‘‘top’’ 324 genes (median H3Y41ph overlap score >0.2);
right panel, blanketed genes, H3Y41ph overlap score >0.5 (45 genes).
(B) ChIP-seq screenshots showing four examples of H3Y41ph-blanketed genes.
(C) ChIP-seq screenshot showing the reduction in H3Y41ph blanketing at the EGFL7 loci following TG101209 treatment.
(D) Genes were ranked based on their median H3Y41ph overlap for both our data (left bar) and that of Rui et al. (2010) (right bar); genes with equal scores were
ranked randomly. Genes showing amedian overlap >0.2were classed as being blanketed in the corresponding data set (blue portion of bar). Lineswere projected
from the rank of the top most blanketed genes (median overlap >0.5; red portion of bar) from our data to the corresponding rank in the Rui et al. data (left panel)
and vice versa (right panel).
(E) GREAT database mouse phenotypes associated with the blanketed genes in HEL cells and the lymphoid cell line K1106.
See also Figure S3 and Tables S1 and S2.et al., 2010) revealed that these genes are critical for myelopoie-
sis, especially erythropoiesis and megakaryopoiesis (Figure 3E).
To further test this hypothesis, we analyzed a published data set
of H3Y41ph in a lymphoid cell line, K1106 (Rui et al., 2010). Inter-
estingly, the genes blanketed by H3Y41ph in this data set were
identified by the GREAT database to be germane to B-lympho-
poiesis (Figure 3E).
Finally, when we intersected the two data sets, we found that
the heavily blanketed gene sets in the two cell types show very
little overlap (Figure 3D). These data suggest that H3Y41ph may
uniquely delineate genes that define a particular cell lineage.
Consistent with this concept is the fact that another indepen-
dent gene set enrichment analysis of the most highly blanketed474 Cell Reports 2, 470–477, September 27, 2012 ª2012 The Authorgenes in HEL cells (using the Database for Annotation, Visuali-
zation and Integrated Discovery: DAVID) (Huang da et al.,
2009) shows that these genes are primarily expressed in
myeloid cells (Figure S3D), and in contrast, the genes most
blanketed by H3Y41ph in K1106 cells are those primarily ex-
pressed in lymphoid tissues (Figure S3D).
DISCUSSION
Two decades of research have firmly established that a key
function of cytoplasmic JAK2 is to mediate cytokine-induced
intracellular signaling. The data presented here challenge
the view that JAK2 is functionally restricted to the cytoplasms
in this signaling pathway. They indicate that JAK2 can phos-
phorylate chromatin at H3Y41 and that this modification takes
place on a number of genes previously linked to the JAK/STAT
pathway. Unfortunately our attempts to localize JAK2 at chro-
matin with ChIP assays have been unsuccessful. This most likely
reflects the transient nature of JAK20s interaction with chro-
matin, which is in contrast to the MAPK family of enzymes that
have a consensus DNA binding motif and have been success-
fully localized at chromatin (Hu et al., 2009). Nevertheless, we
have demonstrated in various cell types that H3Y41ph is a reli-
able marker for JAK20s activity at chromatin (Dawson et al.,
2009). The data reported here show that H3Y41ph is coincident
with STAT5 at several loci and that both these events are
dynamically modulated at the regulatory elements of cytokine-
activated genes. Together, these data establish a previously
unrecognized nuclear component of the JAK/STAT signaling
pathway.
Coincidence of H3Y41ph and STAT5 (Table S1) is seen only
at a subset of the total number of genes marked by H3Y41ph
or STAT5. Since STAT5 is activated by multiple pathways (Lim
and Cao, 2006), genes bound by STAT5 alone may represent
interplay with alternative kinases, modifying distinct sites on
histones. Alternatively, STAT function at certain sites may not
require the cooperation of a kinase, but may depend, for
example, upon the recruitment of specific coactivator/repressor
complexes. Similarly, the genes marked by H3Y41ph alone may
represent genes regulated by other STAT family members or by
a STAT-independent pathway (Dawson et al., 2009). In fact,
when we cross-referenced our data with the published STAT1
and STAT2 ChIP-seq data sets performed in K562 cells (another
erythroid leukemia cell line), we found that a further 10% of the
H3Y41ph sites not bound by STAT5 are bound by STAT1/2
(data not shown). A further possible explanation for H3Y41ph
peaks that do not overlap STAT5 binding sites is that H3Y41ph
is laid down by at least one other kinase (Dawson et al., 2009;
Griffiths et al., 2011), which may function independently of
STATs.
The data presented here have implications beyond the JAK/
STAT pathway; global analysis of H3Y41ph suggests that this
modification behaves differently to other well-characterized
histone modifications, such as lysine acetylation and methyla-
tion, which are often linked to active genes, but their global
levels are not regulated by any single signaling pathway. In
contrast, H3Y41ph marks a specific set of genes stimulated
by a specific signaling pathway and blankets a set of key
lineage-specific hematopoietic genes. Moreover, the data
presented here provide further evidence that signal-trans-
ducing kinases can extend their activity to chromatin. Since
many of these pathways have been the focus of intense drug
discovery programs, the identification of a nuclear component
of kinase cascades increases the scope for future therapeutic
intervention.
EXPERIMENTAL PROCEDURES
Cell Culture
HEL, TF-1, and SET-2 cells were grown at 37C and 5% CO2 in RPMI-1640
(Sigma-Aldrich) supplemented with 10%–20% fetal calf serum, 1% peni-
cillin/streptomycin, and 10 ng/ml IL3 (TF-1 only).CelChIP-seq and ChIP-PCR Analysis
Chromatin immunoprecipitation was performed as previously described
(Dawson et al., 2009). Immunoprecipitated DNA was either amplified for
sequencing or analyzed on an ABI7900 RT-PCR machine using TaqMan
PCR mastermix according to the manufacturer’s instructions (see Extended
Experimental Procedures for primers/probes).
Gene Expression Analysis
Messenger RNA (mRNA) was prepared using the QIAGEN RNeasy kit accord-
ing to the manufacturer’s instructions. Complementary DNA (cDNA) was
prepared using Superscript III reverse transcriptase (Invitrogen) and analyzed
on an ABI7900 RT-PCR machine using power SYBR green PCR mastermix
according to the manufacturer’s instructions (see Extended Experimental
Procedures for primers).
JAK2 Inhibitors
TG101209, TargeGen Inc. (San Diego, CA, USA) and AT9283, Astex Pharma-
ceuticals, were used at 1 mM and 300 nM, respectively, for 4 hr.
Density Profiling and Genome-wide Feature Analysis
BED files were created from uniquely mapped reads extended to 200 bp and
used to create genome-wide density profiles as described (Wilson et al., 2009).
For genome-wide feature analysis, regions of 10 kb width were extracted and
the mean density plotted normalized relative to the total number of sequence
reads in the corresponding data sets. Heat maps were plotted using the same
data and ranked based on the ratio of signal at the central 2 kb divided by the
average signal across the 10 kb region. To examine global relationships
between H3K4me3 and H3Y41ph, TSSs were binned into 10 cohorts of
descending H3K4me3 levels. For quantile normalization, TSSs were ranked
relative to the quantity of H3K4me3 and H3Y41ph sequence tags within
±500 bp of the TSS and displayed using the kde2d R function for kernel density
plots (Venables and Ripley, 2002).
Identification of Blanketed Genes
Refseq genes were split into 10 equally sized regions and two measures
were calculated for each: the proportion of bases showing significant normal-
ized H3Y41ph sequence tag score >10 (‘‘overlap’’) and sum of normalized
H3Y41ph read counts per base (‘‘density’’). Both measures were highly corre-
lated (Spearman correlation = 1.00, p < 2 3 1016). Genes within 50 kb of the
centromere or less than 2.5 kb were removed. Of the 19,067 unique genes
analyzed, 1,009 showed H3Y41ph coverage. A histogram of the median
H3Y41ph overlap of each gene identified a subset of genes with high levels
of protracted gene coverage. Genes were classified as ‘‘blanketed’’ or ‘‘highly
blanketed’’ for H3Y41ph if the overlap was greater than 20% (324 genes) or
50% (45 genes), respectively. Three control gene sets were created of
a similar size to the blanketed gene list: active genes (based on H3K4me3
read density at the promoter), active genes with no H3Y41ph, and genes
with H3Y41ph in the promoter but not across the gene body. Functional
gene set analysis was conducted using the DAVID tool (Huang da et al.,
2009).
Peak Analysis
Peak calling for the STAT5 and H3Y41ph data sets was performed using
Findpeaks 3.1 (Fejes et al., 2008) and MACs (Zhang et al., 2008). In addition,
STAT5 peaks were called using PeakSeq (Rozowsky et al., 2009). Peaks called
by all programs were retained and filtered further based on Findpeaks 3.1
peaks in the control IgG ChIP-seq data set, distance of more than 100 kb of
any RefSeq or University of California Santa Cruz (UCSC) annotated gene,
and more than 70% of repetitive sequence. De novo motif discovery was per-
formed using Multiple Expectation Maximization for Motif Elicitation (MEME)
with the central 100 bp of STAT5 peaks (Bailey et al., 2009) with default
settings.
Overlap between STAT5- and H3Y41ph-enriched regions was determined
based on peaks that overlapped by at least one base pair and also determined
for STAT1/STAT2 peaks in K562 cells from the ENCODE project (Zhang et al.,
2007). Statistical significance of overlaps was calculated by performing 1,000
random permutations and a nonparametric Wilcoxon rank-sum test under thel Reports 2, 470–477, September 27, 2012 ª2012 The Authors 475
NULL hypothesis that STAT and H3Y41ph enrichments are independent of
one another.
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